Cargando…

Synergism of Checkpoint Inhibitors and Peptide Receptor Radionuclide Therapy in the Treatment of Pituitary Carcinoma

CONTEXT: Aggressive pituitary tumors that have progressed following temozolomide have limited treatment options. Peptide receptor radionuclide therapy and immunotherapy may have a complementary role in the management of these tumors. METHODS: We provide follow-up data on a previously reported patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Andrew L, Tabar, Viviane, Young, Robert J, Cohen, Marc, Cuaron, John, Yang, T Jonathan, Rosenblum, Marc, Rudneva, Vasilisa A, Geer, Eliza B, Bodei, Lisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402930/ https://www.ncbi.nlm.nih.gov/pubmed/34466766 http://dx.doi.org/10.1210/jendso/bvab133

Ejemplares similares

Perioperative management of endoscopic transsphenoidal pituitary surgery
por: Hanson, Martin, et al.
Publicado: (2020)

Integration of an enhanced recovery after surgery program for patients undergoing pituitary surgery
por: Flukes, Stephanie, et al.
Publicado: (2022)

Comparison of Radiographic Approaches to Assess Treatment Response in Pituitary Adenomas: Is RECIST or RANO Good Enough?
por: Imber, Brandon S, et al.
Publicado: (2019)

THU040 Different Patient Versus Provider Perspectives On Living With Cushing’s Disease
por: Halstrom, Amanda, et al.
Publicado: (2023)

The Effects of Peptide Receptor Radionuclide Therapy on the Neoplastic and Normal Pituitary
por: Marques, Pedro
Publicado: (2023)

EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides
por: Handkiewicz-Junak, Daria, et al.
Publicado: (2018)

Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
por: Elston, Marianne S., et al.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?
por: Bodei, Lisa, et al.
Publicado: (2020)

Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience
por: Giuffrida, G, et al.
Publicado: (2019)

Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach
por: Kgatle, Mankgopo M., et al.
Publicado: (2021)

Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib
por: Nonnekens, Julie, et al.
Publicado: (2016)

Clinical radionuclide therapy dosimetry: the quest for the “Holy Gray”
por: Brans, B., et al.
Publicado: (2007)

Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?
por: Qian, Xinye, et al.
Publicado: (2022)

Peptide Receptor Radionuclide Therapy
por: Hofland, Johannes, et al.
Publicado: (2022)

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
por: Zaknun, John J., et al.
Publicado: (2013)

Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
por: Bodei, L., et al.
Publicado: (2013)

Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice
por: Prasad, Vikas, et al.
Publicado: (2020)

Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma
por: Beug, Shawn T., et al.
Publicado: (2017)

Erdheim-Chester disease among neuroinflammatory syndromes: the case for precision medicine
por: de la Fuente, Macarena I., et al.
Publicado: (2020)

SUN-274 Pituitary Macroadenoma Treated with Peptide Receptor Radionuclide Therapy in a Patient with Common Variable Immunodeficiency - Case Report
por: Brodowska-Kania, Dorota, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function
por: Jessel, Shlomit, et al.
Publicado: (2022)

Peptide Receptor Radionuclide Therapy in Thyroid Cancer
por: Gubbi, Sriram, et al.
Publicado: (2022)

Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics
por: Chakraborty, Kushal, et al.
Publicado: (2023)

Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer
por: Wierstra, Peter, et al.
Publicado: (2019)

Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment
por: Kleinendorst, Simone C., et al.
Publicado: (2022)

Derivation of Diverse Hormone-Releasing Pituitary Cells from Human Pluripotent Stem Cells
por: Zimmer, Bastian, et al.
Publicado: (2016)

SAT623 Everolimus For Treatment-refractory Prolactinomas
por: Lin, Andrew L, et al.
Publicado: (2023)

Poxvirus immunotherapies in combination with immune checkpoint inhibitors synergize to eliminate tumors in a mouse tumor model
por: Foy, Susan P, et al.
Publicado: (2013)

Publisher Correction: Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma
por: Beug, Shawn T., et al.
Publicado: (2018)

Kidney Dosimetry in (177)Lu and (90)Y Peptide Receptor Radionuclide Therapy: Influence of Image Timing, Time-Activity Integration Method, and Risk Factors
por: Guerriero, F., et al.
Publicado: (2013)

Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells
por: Hoffmann, Michèle J., et al.
Publicado: (2021)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Veppil Muralidharan, Somsundar, et al.
Publicado: (2017)

BET bromodomain inhibitors synergize with ATR inhibitors in melanoma
por: Muralidharan, Somsundar Veppil, et al.
Publicado: (2017)

Improved Quality of Life in Patients Treated with Peptide Radionuclides
por: Traub-Weidinger, T, et al.
Publicado: (2011)

The Current Role of Peptide Receptor Radionuclide Therapy in Meningiomas
por: Fodi, Christina-Katharina, et al.
Publicado: (2022)

Peptide Receptor Radionuclide Therapy (PRRT): Innovations and Improvements
por: Merola, Elettra, et al.
Publicado: (2023)

Immune checkpoint blockade can synergize with radiation therapy, even in tumors resistant to checkpoint monotherapy
por: Dörrie, Jan
Publicado: (2016)

Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors
por: Kobayashi, Tomoko, et al.
Publicado: (2021)

DNA-PKcs inhibitors sensitize neuroendocrine tumor cells to peptide receptor radionuclide therapy in vitro and in vivo
por: Reuvers, Thom G.A., et al.
Publicado: (2023)

SUN-923 Combination Immune Checkpoint Inhibitor Therapy for ACTH-Secreting Pituitary Carcinoma
por: de Filette, Jeroen M K, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_370av7ho3ntj9ld2v0f7vdeulf